The CLPTM1L (Cleft Lip and Palate Transmembrane 1-Like) protein, encoded by the *CLPTM1L* gene on chromosome 11q13. is a transmembrane protein implicated in diverse cellular processes, including apoptosis regulation, DNA repair, and chemoresistance. Initially identified for its homology to RAD51. a key DNA repair protein, CLPTM1L gained prominence due to its association with cancer susceptibility. Genome-wide studies linked the 11q13 locus (containing *CLPTM1L* and *FADS1/3*) to increased risk for lung, pancreatic, and other cancers. CLPTM1L is overexpressed in multiple cancers and promotes tumor progression by enhancing cell survival, proliferation, and resistance to chemotherapy.
CLPTM1L antibodies are critical tools for studying its expression, localization, and functional roles. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in biomarker research and mechanistic studies. CLPTM1L's interaction with proteins like BIRC6 (an apoptosis inhibitor) and its role in modulating Wnt/β-catenin or EGFR pathways highlight its therapeutic relevance. Antibodies targeting specific domains (e.g., extracellular loops or cytoplasmic regions) help dissect its structure-function relationships.
Recent studies also explore CLPTM1L’s potential as a therapeutic target, with antibodies under investigation for diagnostic or blocking applications. However, challenges remain in understanding its precise molecular mechanisms and tissue-specific roles. CLPTM1L antibodies thus serve as essential reagents in both basic research and translational oncology.
(Word count: 247)